QTRX

Quanterix Corp

Add to Watchlist

Advanced Chart

5.650

+0.370(+7.010%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

5.820

Open

5.570

VWAP

5.64

Vol

295.98K

Mkt Cap

204.98M

Low

5.490

Amount

1.67M

EV/EBITDA(TTM)

Total Shares

38.27M

-84.15M

EV/OCF(TTM)

P/S(TTM)

1.47

Quanterix Corporation is a life sciences company. The Company is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in low concentrations in blood, serum, and other fluids. The Company's Simoa technology is based on traditional enzyme-linked immunosorbent assay (ELISA) technology. Its products include HD-X, SR-X, SP-X, Simoa assays and consumables, and NfL antibodies and NfL ELISA kits. It also offers contract research services for customers through its Accelerator Laboratory, which provides customers with access to Simoa technology and supports multiple projects and services, including sample testing, homebrew assay development and custom assay development. It has completed over 2,200 projects for 480 customers using its Simoa platforms.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

38.24M

+6.78%

34.83M

+1.31%

28.27M

-11.83%

Estimates Revision

The market is revising Downward the revenue expectations for Quanterix Corporation (QTRX) for FY2025, with the revenue forecasts being adjusted by -6.01% over the past three months. During the same period, the stock price has changed by -27.66%.

Revenue Estimates for FY2025

Revise Downward

-6.01%

In Past 3 Month

Stock Price

Go Down

-27.66%

In Past 3 Month

4 Analyst Rating

114.69% Upside

Wall Street analysts forecast QTRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QTRX is 12.13 USD with a low forecast of 7.50 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

2 Hold

0 Sell

Moderate Buy

114.69% Upside

Current: 5.650

Low

7.50

Averages

12.13

High

18.00

114.69% Upside

Current: 5.650

Low

7.50

Averages

12.13

High

18.00

Leerink Partners

Puneet Souda

Buy

Hold

Downgrades

$12 → $8

2025-04-30

Reason

Leerink Partners

Puneet Souda

Price Target

$12 → $8

2025-04-30

Downgrades

Buy

Hold

Reason

Scotiabank

Sung Nam

Buy

Maintains

$28 → $18

2025-03-25

Reason

Scotiabank

Sung Nam

Price Target

$28 → $18

2025-03-25

Maintains

Buy

Reason

Scotiabank analyst Sung Ji Nam lowered the firm's price target on Quanterix to $18 from $28 and keeps an Outperform rating on the shares. Despite the relatively stronger revenue growth performance compared to its peer group, the company's shares underperformed over the last year, the analyst tells investors. While the firm thinks the operating synergy targets are reasonable, it is less certain about the top line growth potential.

Canaccord Genuity

Kyle Mikson

Strong Buy

Maintains

$20 → $15

2025-03-18

Reason

Canaccord Genuity

Kyle Mikson

Price Target

$20 → $15

2025-03-18

Maintains

Strong Buy

Reason

Canaccord lowered the firm's price target on Quanterix (QTRX) to $15 from $20 and keeps a Buy rating on the shares. The firm said they continue to viewthe company as undervalued following the company's solid performance in 4Q24. That said, they recognize negative investor sentiment on its merger with Akoya Biosciences (AKYA) may negatively impact share price performance going forward.

TD Cowen

Daniel Brennan

Hold

Maintains

$14 → $16

2024-11-13

Reason

TD Cowen

Daniel Brennan

Price Target

$14 → $16

2024-11-13

Maintains

Hold

Reason

TD Cowen raised the firm's price target on Quanterix to $16 from $13.50 and keeps a Hold rating on the shares. The firm said Q3 results beat with sales and its Alzheimer's blood testing sales are nascent, though drivers are coming into place for traction in 2025 and beyond.

Scotiabank

Sung Nam

Buy

Maintains

$32 → $28

2024-08-12

Reason

Scotiabank

Sung Nam

Price Target

$32 → $28

2024-08-12

Maintains

Buy

Reason

TD Cowen

Daniel Brennan

Hold

Maintains

$17 → $15

2024-08-09

Reason

TD Cowen

Daniel Brennan

Price Target

$17 → $15

2024-08-09

Maintains

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Quanterix Corp (QTRX.O) is -4.01, compared to its 5-year average forward P/E of -18.89. For a more detailed relative valuation and DCF analysis to assess Quanterix Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-18.89

Current PE

-4.01

Overvalued PE

-8.43

Undervalued PE

-29.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-14.70

Current EV/EBITDA

0.74

Overvalued EV/EBITDA

-1.72

Undervalued EV/EBITDA

-27.69

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

8.98

Current PS

1.52

Overvalued PS

15.10

Undervalued PS

2.86